CASI Pharmaceuticals (NASDAQ:CASI) just reported results for the fourth quarter of 2023.
- CASI Pharmaceuticals reported earnings per share of -45 cents. This was below the analyst estimate for EPS of -24 cents.
- The company reported revenue of $6.87 million.
- This was 26.95% worse than the analyst estimate for revenue of $9.41 million.